News Releases

Twist Bioscience to Present at Upcoming Virtual Conferences

November 24, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 24, 2021-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the following upcoming virtual investor conferences:

  • Piper Sandler 33rd Annual Virtual Healthcare Conference on Monday, November 29; fireside chat at 10:00 a.m. Eastern Time.
  • 4th Annual Evercore ISI HealthCONx Conference on Tuesday, November 30; fireside chat at 10:30 a.m. Eastern Time.

The fireside chats can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the fireside chats will be archived for a period of 30 days following the conclusion of the live events.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Twist Bioscience
Angela Bitting
SVP, Corporate Affairs

Source: Twist Bioscience